Partner, Third Rock Ventures
Vice President for Corporate Engagement, Rose-Hulman Institute of Technology
Founder and CEO of Brooks Bell Inc.
Head of global research and development at Life Technologies
Founder, The Haul Company
Director, Life Sciences Institute, University of Michigan
Founder, Young Inventors
CEO and co-founder of BoostSuite
If you’re keeping track, FDA drug approvals have been on a tear in the past month with several decisions coming well ahead of their targeted dates. And then there’s Sarepta Therapeutics.
Late Thursday, the FDA announced approval of the Cambridge,... Read more »
An osteoporosis drug developed by Amgen now has marketing approval in Europe, but it carries a warning that the medicine can raise the risk of cardiovascular problems.
Romosozumab (Evenity) treats postmenopausal woman who have osteoporosis, a disease that weakens bones, making... Read more »
Iterum Therapeutics’ bid to bring patients a new antibiotic that’s safer than currently available drugs has fallen short of the main efficacy goal of a late-stage clinical trial. But the company is pinning its hopes on another Phase 3 study that... Read more »
Palo Alto, CA-based BridgeBio Pharma (NASDAQ: BBIO) has named Eli Wallace as its chief scientific officer in residence for oncology. In this role, Wallace will oversee the company’s current drug discovery projects, while helping identify and develop new oncology programs.... Read more »
It’s been a roller-coaster year for those hoping for new drugs to treat Alzheimer’s disease, a leading cause of death with rising treatment costs and no clear answer yet as to its cause.
Clearing proteins, such as amyloid and tau, was... Read more »
A Roche immunotherapy has won an additional FDA approval as a first-line treatment for non-small lung cancer, bolstering the product’s competitive stance versus one from Merck.
The FDA approved atezolizumab (Tecentriq) for adults whose non-squamous non-small cell lung cancer (NSCLC) is... Read more »
Two venture-backed startups that have developed technologies intended to speed up the drug discovery and development process are combining those tools in a bid to achieve their goals together.
San Francisco-based Atomwise has developed deep learning techniques for use in structure-based... Read more »
[Updated 12/4/19, 4:01 p.m. ET. See below.] Veracyte, a company whose tests help physicians make treatment decisions, is adding technology from NanoString to the fold to expand its diagnostic capabilities.
South San Francisco-based Veracyte (NASDAQ: VCYT) announced Tuesday... Read more »
Japanese drug giant Astellas Pharma announced late Monday it has agreed to buy Audentes Therapeutics, which is developing gene therapies for rare neuromuscular diseases.
It’s an all-cash deal worth $3 billion, with the Astellas offer of $60 per share representing a... Read more »
The FDA on Monday approved a Global Blood Therapeutics treatment for sickle cell disease, three months before the agency’s decision was expected.
Regulators evaluated the drug, voxelotor (Oxbryta), under a pathway that allows for a speedier review using less evidence than... Read more »
Ferring Pharmaceuticals and Blackstone Life Sciences have formed a new company to commercialize a bladder cancer gene therapy that is currently in late-stage clinical testing.
The new company, FerGene, is a subsidiary of Swiss pharmaceutical company Ferring, which is investing $170... Read more »
In startup world these days, the word “biotech” is increasingly accompanied by “computational” and two, two-letter initialisms: AI and ML.
Those tools—artificial intelligence and machine learning, respectively—have been around for decades, but in recent years have become faster and cheaper, accelerating... Read more »
Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators.
As the Federal Trade Commission reviewed Bristol’s (NYSE:... Read more »
Lucence, a genomic medicine company developing blood-based tests for cancer screening and treatment selection, announced this week the close of a $20 million Series A funding round led by IHH Healthcare.
CEO and founder Min-Han Tan (pictured) says the investment will... Read more »
Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020. These are among the major findings of a survey of... Read more »
A drug candidate once shelved by Takeda Pharmaceutical (NYSE: TAK) has found new life within Roivant Sciences spinout Myovant as a potential once-daily oral hormone therapy for patients with advanced prostate cancer.
The Brisbane, CA-based biotech company (MYSE: MYOV)... Read more »
Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in which arteries become clogged with substances such as fats and cholesterol, which restricts blood flow.
Based in Mountain View, CA, Underdog... Read more »
[Updated 5:55 p.m. See below.] Rodin Therapeutics has limited data from human studies about its neurodegeneration drug, but the company’s new approach to treating brain disorders has proven attractive enough for Alkermes to plunk down $100 million to buy... Read more »
Lung injuries connected to the use of electronic cigarettes have topped 2,000 and killed 40 people, according to the Centers for Disease Control and Prevention.
It’s still unclear whether the cases are tied to legally sold products or devices modified by... Read more »
The list of activities our smartphones can control grows daily. Transfer money? It’s simple. Order groceries? That, too. Turn off the bedroom lights? Check.
How about contraception?
Advancing new forms of birth control is a central focus at Daré Bioscience (NASDAQ:... Read more »
Launched just last year, artificial intelligence-powered drug discovery company X-37 now has raised $14.5 million in Series A financing to expand its development programs.
Co-founded by Atomwise and a team from Velocity Pharmaceutical Development, the San Francisco, CA-based company uses Atomwise’s... Read more »
These are heady times for neuroscience research. Startups developing new approaches to brain disorders are raising money to advance their discoveries toward clinical trials. One failed neuro drug is getting another shot.
On Nov. 19 in San Francisco, we’ll... Read more »
From Our Partners · Special Report
Advice for funding and future transformational opportunities
From Our Editors · Special Report
Key indicators & expert insight from industry leaders
Xconomy
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
CEO, i-Human Patients.
Executive Director, Center for Open Innovation, UC Berkeley
CEO and Founder, ExploraMed Development
Professor of Bioengineering, Stanford University
Director, Intel Capital
W20 chairman and CEO
Vice Chairman for Innovation of SRI International
Co-Founder and CEO, DNAnexus
President and CEO of Barracuda Networks
Assoc. Dir. Of Mobility Research, Carnegie Mellon Silicon Valley
CEO and Co-Founder, Solazyme
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
